Cryonix Acquires Bluechiip Assets in Strategic Move to Lead Biosample Management Transformation
In a strategic and decisive step toward transforming the future of biosample integrity, Cryonix Group (Cryonix LLC) has completed the asset acquisition of Bluechiip, a global pioneer in advanced biosample tracking and cryogenic management technology.
With the competitive transaction finalised, Bluechiip is recapitalised, restructured, and reinvigorated - now operating as part of a broader Cryonix platform designed to lead the next generation of sample management, traceability, and life sciences storage and logistics.
“We’re excited to welcome Bluechiip’s industry-leading offerings into Cryonix,” said Damian Cullen, Co-Founder and President of Cryonix. “This marks the start of a new chapter - where the proven excellence of Bluechiip is empowered by our passionate focus on execution, innovation-driven investment, and customer success.”
The acquisition reflects Cryonix’s mission to not simply preserve the Bluechiip brand, but to scale it globally - with smarter traceability, enhanced digital infrastructure, and a refined commercial model. Backed by new capital and deep operational expertise, Cryonix aims to unlock the full potential of Bluechiip’s MEMS-based tracking and cryo-sensing technology.
“At Cryonix, we see biosample management not as a back-office function - but as a critical pillar of modern medicine, research, and regenerative science,” Cullen added. “The market is ready for a smarter, more secure standard. And we’re ready to build it.”
Existing Bluechiip customers and partners can expect zero disruption to service. All commercial relationships, distribution channels, and product lines remain in place - now supported by a stronger, more focused Cryonix team.
Over the coming months, Cryonix will roll out:
- Enhanced product and software capabilities
- Expanded distribution partnerships
- Upgraded service infrastructure across core markets
In a world where a single biosample can represent a patient’s future, the stakes for traceability and security have never been higher. Cryonix is betting on trust as a differentiator - and this acquisition places them at the forefront of an industry under transformation.
“This isn’t just about devices. It’s about safeguarding life-changing material across time zones, temperatures, and treatment journeys,” Cullen concluded. “We’re building the company that life sciences can count on - sample by sample.”
Damian Cullen
President, Cryonix Group
📧 [email protected]
🌐 www.bluechiip.com